Ambroxol for new and early dementia with Lewy bodies
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether ambroxol (a mouth medicine) can help people with new or early dementia with Lewy bodies (DLB) or mild cognitive impairment linked to DLB. Participants take the medicine for about 18 months while the study tracks safety and changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 50 to 85, and you’ve been diagnosed with DLB or DLB-related mild cognitive impairment
- Your memory test score (MMSE) is 15 or higher
- You can give informed consent and follow study visits and procedures
- You’re able to take ambroxol by mouth yourself or with a caregiver (starting on Day 1) throughout the study
- You’re willing to provide blood samples for genetic testing (APOE and GBA)
- If you’re female, you must meet pregnancy-prevention rules (not pregnant/breastfeeding) and use approved birth control or be past childbearing years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how brain changes affect attention and thinking in people with Lewy body dementia. It includes brain scans, an EEG, and a medication option to see if it helps with symptoms.
This trial tests a medicine normally used for high blood pressure (terazosin) to see if it can improve thinking or slow down decline in people with dementia with Lewy bodies. It's an early-stage study, so the goal is also to check safety.
This trial tests whether shining a special red light on the head can improve symptoms, daily life, and brain activity in people with dementia with Lewy bodies. The treatment is non-invasive and may help with thinking and movement problems.
This study tests an eHealth program together with a patient-and-caregiver support program, along with a medicine called ambroxol. It aims to see whether this combined approach is safe and helpful for people with dementia with Lewy bodies (or early memory changes from it).
This study tests a medicine called ambroxol, which may slow down the progression of Lewy body dementia. It aims to see if it can improve memory, thinking, and movement symptoms.
This trial studies whether ambroxol (or a placebo) can slow the progression of Parkinson’s disease. It may help by aiming to change how the disease develops over time.
Hear when a new Dementia With Lewy Bodies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.